ID   LN-319
AC   CVCL_3958
SY   LN 319; LN319
DR   BTO; BTO:0002215
DR   AddexBio; C0005001/54
DR   BioSample; SAMN03151824
DR   BioSample; SAMN10988411
DR   CCLE; LN319_CENTRAL_NERVOUS_SYSTEM
DR   Cell_Model_Passport; SIDM01626
DR   Cosmic; 849864
DR   Cosmic; 2367493
DR   Cosmic; 2516027
DR   DepMap; ACH-000128
DR   GEO; GSM397667
DR   GEO; GSM397668
DR   IARC_TP53; 2572
DR   PharmacoDB; LN319_843_2019
DR   Wikidata; Q54902776
RX   PubMed=7693337;
RX   PubMed=7732013;
RX   PubMed=9842975;
RX   PubMed=10416987;
RX   PubMed=14614447;
RX   PubMed=14655754;
RX   PubMed=17595512;
RX   PubMed=21406405;
RX   PubMed=22570425;
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v11_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00450.
CC   Doubling time: 51 hours (PubMed=9842975); 45 hours (PubMed=25984343).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg15Ile (c.44G>T); Zygosity=Homozygous (CCLE).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=7732013; PubMed=10416987; PubMed=14614447; CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.07%; Native American=0.71%; East Asian, North=1.65%; East Asian, South=0%; South Asian=1.15%; European, North=65.6%; European, South=29.81% (PubMed=30894373).
ST   Source(s): PubMed=22570425
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 14,19
ST   D21S11: 30,31
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 9
ST   D8S1179: 12
ST   FGA: 19,26
ST   Penta D: 9,13
ST   Penta E: 15,17
ST   TH01: 9,9.3
ST   TPOX: 8,12
ST   vWA: 15,18
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_6845 ! LN-992
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 23
//
RX   PubMed=7693337;
RA   Li H., Hamou M.-F., de Tribolet N., Jaufeerally R., Hofmann M.,
RA   Diserens A.-C., Van Meir E.G.;
RT   "Variant CD44 adhesion molecules are expressed in human brain
RT   metastases but not in glioblastomas.";
RL   Cancer Res. 53:5345-5349(1993).
//
RX   PubMed=7732013; DOI=10.1073/pnas.92.9.3963;
RA   Flaman J.-M., Frebourg T., Moreau V., Charbonnier F., Martin C.,
RA   Chappuis P., Sappino A.-P., Limacher J.-M., Bron L., Benhattar J.,
RA   Tada M., Van Meir E.G., Estreicher A., Iggo R.D.;
RT   "A simple p53 functional assay for screening cell lines, blood, and
RT   tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:3963-3967(1995).
//
RX   PubMed=9842975; DOI=10.1002/(sici)1097-0215(19981218)79:6<640::aid-ijc15>3.0.co;2-z;
RA   Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N.,
RA   Krajewski S., Reed J.C., von Deimling A., Dichgans J.;
RT   "Predicting chemoresistance in human malignant glioma cells: the role
RT   of molecular genetic analyses.";
RL   Int. J. Cancer 79:640-644(1998).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=14614447; DOI=10.1038/sj.onc.1207198;
RA   Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.;
RT   "CP-31398, a novel p53-stabilizing agent, induces p53-dependent and
RT   p53-independent glioma cell death.";
RL   Oncogene 22:8233-8245(2003).
//
RX   PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x;
RA   Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.;
RT   "P-glycoprotein and multidrug resistance-associated protein mediate
RT   specific patterns of multidrug resistance in malignant glioma cell
RT   lines, but not in primary glioma cells.";
RL   Brain Pathol. 13:482-494(2003).
//
RX   PubMed=17595512; DOI=10.1159/000104150;
RA   Rieger J., Frank B., Weller M., Wick W.;
RT   "Mechanisms of resistance of human glioma cells to Apo2
RT   ligand/TNF-related apoptosis-inducing ligand.";
RL   Cell. Physiol. Biochem. 20:23-34(2007).
//
RX   PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112;
RA   Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.-H.,
RA   Moncayo G., Hemmings B.A.;
RT   "MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta
RT   signaling pathway in human glioblastoma.";
RL   Cancer Res. 71:2392-2402(2011).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//